2024
Public Health Impact of FDA’s Request for Additional Safety Data on Cytisine for Tobacco Cessation
Reddy K, Paltiel A, Freedberg K, Rigotti N. Public Health Impact of FDA’s Request for Additional Safety Data on Cytisine for Tobacco Cessation. JAMA Health Forum 2024, 5: e242647. PMID: 39177985, PMCID: PMC11344233, DOI: 10.1001/jamahealthforum.2024.2647.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAlkaloidsAzocinesFemaleHumansLife ExpectancyMaleMiddle AgedPublic HealthQuinolizidine AlkaloidsQuinolizinesSmoking CessationSmoking Cessation AgentsUnited StatesUnited States Food and Drug AdministrationYoung AdultConceptsPublic health benefitsCessation medicationsSmoking cessationStop smokingLife yearsLong-term abstinenceCivilian noninstitutionalized adultsTobacco cessation treatmentTobacco cessation medicationsPotential public health benefitsPopulation-level life expectancyLife expectancySmoking cessation medicationsLife expectancy gainsHealth benefitsPotential public health impactPublic health impactSmoking cessation aidTobacco cessationNoninstitutionalized adultsNoninstitutionalized populationMain OutcomesCessation treatmentCessation aidsYear of availability
2021
Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment
Paltiel AD, Zheng A, Schwartz JL. Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment. Annals Of Internal Medicine 2021, 174: m20-7866. PMID: 33395345, PMCID: PMC7787166, DOI: 10.7326/m20-7866.Peer-Reviewed Original ResearchCommunicable Disease ControlCOVID-19COVID-19 VaccinesDisease ProgressionEfficiencyHumansPandemicsPneumonia, ViralSARS-CoV-2Time FactorsUnited StatesUnited States Food and Drug Administration
2011
Medical Device Innovation — Is “Better” Good Enough?
Suter LG, Paltiel AD, Rome BN, Solomon DH, Golovaty I, Gerlovin H, Katz JN, Losina E. Medical Device Innovation — Is “Better” Good Enough? New England Journal Of Medicine 2011, 365: 1464-1466. PMID: 22010911, PMCID: PMC3570242, DOI: 10.1056/nejmp1109285.Peer-Reviewed Original ResearchAgedComorbidityDevice ApprovalHumansKnee ProsthesisLife ExpectancyMiddle AgedModels, StatisticalProsthesis FailureReoperationRiskUnited StatesUnited States Food and Drug Administration
2009
Price, Performance, and the FDA Approval Process: The Example of Home HIV Testing
Paltiel AD, Pollack HA. Price, Performance, and the FDA Approval Process: The Example of Home HIV Testing. Medical Decision Making 2009, 30: 217-223. PMID: 19429837, PMCID: PMC2897074, DOI: 10.1177/0272989x09334420.Peer-Reviewed Original ResearchMeSH KeywordsDevice ApprovalHIV InfectionsHumansPredictive Value of TestsReagent Kits, DiagnosticUnited StatesUnited States Food and Drug Administration
2006
Rapid HIV testing at home: does it solve a problem or create one?
Walensky RP, Paltiel AD. Rapid HIV testing at home: does it solve a problem or create one? Annals Of Internal Medicine 2006, 145: 459-62. PMID: 16983134, DOI: 10.7326/0003-4819-145-6-200609190-00010.Peer-Reviewed Original ResearchMeSH KeywordsCosts and Cost AnalysisDevice ApprovalFalse Negative ReactionsFalse Positive ReactionsHIV InfectionsHIV-1HIV-2HumansReagent Kits, DiagnosticUnited StatesUnited States Food and Drug AdministrationConceptsRapid HIV testsHome HIV testHIV testHIV testingRapid home HIV testUnidentified HIV infectionRapid HIV testingHIV testing kitsHome HIV testingUndetectable diseaseFalse-negative resultsPublic health crisisHIV infectionHIV riskHIV detectionDrug AdministrationU.S. FoodHome testHIVHealth crisisHome useTesting kitsCareCautious perspectiveGreat need
1996
The FDA And Regulation Of Cost-Effectiveness Claims
Neumann P, Ƶinner D, Paltiel A. The FDA And Regulation Of Cost-Effectiveness Claims. Health Affairs 1996, 15: 54-71. PMID: 8854508, DOI: 10.1377/hlthaff.15.3.54.Peer-Reviewed Original ResearchCost-Benefit AnalysisDrug CostsDrug IndustryEconomics, PharmaceuticalHumansModels, EconomicPrivate SectorStreptokinaseTissue Plasminogen ActivatorUnited StatesUnited States Food and Drug Administration